Clofazimine contributes sustained antimicrobial activity after treatment cessation in a mouse model of tuberculosis chemotherapy

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2864-2869

  Swanson, Rosemary V ^a,b   Ammerman, Nicole C ^a,c   Ngcobo, Bongani ^a   Adamson, John ^a   Moodley, Chivonne ^a   Dorasamy, Afton ^a   Moodley, Sashen ^a   Mgaga, Zinhle ^a,e   Bester, Linda A ^d   Singh, Sanil D ^d   Almeida, Deepak V ^a,c   Grosset, Jacques H ^a,c  

^a AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e HIV Vaccine Trials Network   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; DRUG COMBINATION; ISONIAZID, PYRAZINAMIDE, RIFAMPIN DRUG COMBINATION; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; LUNG; LUNG HOMOGENATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; TREATMENT DURATION; TREATMENT WITHDRAWAL; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; ISONIAZID; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS; WITHHOLDING TREATMENT;

EID: 84964866579     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00177-16     Document Type: Article

References (29)

1. Barry VC, Conalty ML, Gaffney EE. 1956. Antituberculosis activity in the phenazine series; isomeric pigments obtained by oxidation of o-phenylenediamine derivatives. J Pharm Pharmacol 8:1089-1096. http://dx.doi.org/10.1111/j.2042-7158.1956.tb12238.x.
2. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF, Twomey D, Winder F. 1957. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179: 1013-1015. http://dx.doi.org/10.1038/1791013a0.
3. World Health Organization. 2004. Multidrug therapy against leprosy: development and implementation over the past 25 years. WHO/CDS/CPE/CEE/2004.46. World Health Organization, Geneva, Switzerland.
4. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL, Efficacy Subgroup, RESIST-TB. 2013. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 207:1352-1358. http://dx.doi.org/10.1093/infdis/jis460.
5. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
6. World Health Organization. 2013. Multidrug-resistant tuberculosis (MDR-TB). 2013 update. World Health Organization, Geneva, Switzerland.
7. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. 2014. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18:1180-1187. http://dx.doi.org/10.5588/ijtld.14.0100.
8. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. 2014. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 18:1188-1194. http://dx.doi.org/10.5588/ijtld.13.0075.
9. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Trébucq A. 2015. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 19:517-524. http://dx.doi.org/10.5588/ijtld.14.0535.
10. Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH. 2015. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A 112:869-874. http://dx.doi.org/10.1073/pnas.1416951112.
11. Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188:608-612. http://dx.doi.org/10.1164/rccm.201304-0753OC.
12. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, Li M, Li F, Wu M, Zhu Y, Sun H, Gu J, Wang X, Zhang Z. 2015. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 60:1361-1367. http://dx.doi.org/10.1093/cid/civ027.
13. Levy L. 1974. Pharmacologic studies of clofazimine. Am J Trop Med Hyg 23:1097-1109.
14. Mansfield RE. 1974. Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 23:1116-1119.
15. Banerjee DK, Ellard GA, Gammon PT, Waters MF. 1974. Some observations on the pharmacology of clofazimine (B663). Am J Trop Med Hyg 23:1110-1115.
16. Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, Moodley S, Mgaga Z, Tapley A, Bester LA, Singh S, Grosset JH, Almeida DV. 2015. Pharmacokinetics and pharmacodynamics of clofazimine in the mouse model of tuberculosis. Antimicrob Agents Chemother 59:3042-3051. http://dx.doi.org/10.1128/AAC.00260-15.
17. McDougall AC. 1974. Electron microscope studies of the antileprosy drug B663 (clofazimine; Lamprene). Int J Lepr Other Mycobact Dis 42:1-12.
18. Aplin RT, McDougall AC. 1975. Identification of crystals of the riminophenazine compound B663 (Lamprene: clofazimine) in mouse spleen macrophages by thin layer chromatography and mass spectrum analysis. Experientia 31:468-469. http://dx.doi.org/10.1007/BF02026384.
19. Baik J, Rosania GR. 2012. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS One 7:e47494. http://dx.doi.org/10.1371/journal.pone.0047494.
20. Baik J, Stringer KA, Mane G, Rosania GR. 2013. Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response. Antimicrob Agents Chemother 57:1218-1230. http://dx.doi.org/10.1128/AAC.01731-12.
21. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
22. Grosset J, Ji B. 1998. Experimental chemotherapy of mycobacterial diseases, p 51-97. In Gangadharam PRJ, Jenkins PA (ed), Mycobacteria, vol 2. Chemotherapy. Chapman & Hall, New York, NY.
23. Dickinson J, Guy A, Mitchison DA. 1992. Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother 36: 2066-2067. http://dx.doi.org/10.1128/AAC.36.9.2066.
24. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548-551. http://dx.doi.org/10.1128/AAC.36.3.548.
25. Noufflard H, Berteaux S. 1958. Activité antituberculeuse du produit B-663. I. Action in vitro et sur la tuberculose expérimentale de la souris en traitement immédiat (test de protection). Ann Inst Pasteur (Paris) 95: 449-455.
26. Grumbach F. 1960. Activité antituberculeuse expérimentale de deux dérivés de phénazine pigmentée (B 663 et B 720) seuls et associés a d'autres antituberculeux (isoniazide et éthioniamide). Ann Inst Pasteur (Paris) 99:567-585.
27. Union Internationale contre la Tuberculose et les Maladies Respiratoires. 2016. Bulletin de la tuberculose en Afrique francophone. No. 6. Union Internationale contre la Tuberculose et les Maladies Respiratoires, Paris, France.
28. Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria, and the Physicians of the French MDR-TB Cohort. 2015. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 60:188-194. http://dx.doi.org/10.1093/cid/ciu786.
29. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.